#12 - Lars Wilde: Scaling The Model For Psilocybin-Assisted Psychotherapy

<p>Lars Wilde is the President, Chief Business Officer, and Co-founder of COMPASS Pathways. COMPASS is a UK life sciences company that works to expedite the approval and delivery of mental health therapies to patients and focuses primarily on testing psilocybin for use in patients with treatment-resistant depression (TRD). They have 22 trials running through the US and Europe for TRD.</p><p>In this conversation we speak about:</p><ul> <li>His personal journey and battles with anxiety, and seeking psychiatric help</li> <li>The subjective experience of psilocybin and impact of emotional processing and cognitive function</li> <li>Birth of COMPASS</li> <li>The current landscape of the research</li> <li>Models for therapies and how they can scale</li> <li>Research questions that need to be addressed</li> <li>COMPASS decision to patent psilocybin (and what this means for its scientific exploration)</li> <li>Rescheduling psilocybin</li> </ul><p><br><a href="https://mindmedicineaustralia.org.au/donate/">Donate to Mind Medicine Australia</a></p><p><a href="https://mindmedicineaustralia.org.au/chapters-australia-new-zealand/">Join a local chapter</a></p><p><a href="https://compasspathways.com/">COMPASS Pathways</a></p>